AbbVie (ABBV)
(Delayed Data from NYSE)
$200.47 USD
-3.08 (-1.51%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $200.75 +0.28 (0.14%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$200.47 USD
-3.08 (-1.51%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $200.75 +0.28 (0.14%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Lilly's Crohn's Disease Candidate Meets Phase II Study Goals
by Zacks Equity Research
Lilly's (LLY) mirikizumab met primary endpoint and key secondary endpoints in phase II Crohn's disease study.
Go Beyond Bargains: Play 5 Stocks With Rising P/E Instead
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Top Ranked Income Stocks to Buy for May 22nd
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, May 22nd.
Top Ranked Income Stocks to Buy for May 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 21st.
AbbVie's Brain Cancer Candidate Fails in Phase III Study
by Zacks Equity Research
AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.
Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL
by Zacks Equity Research
Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs
by Kinjel Shah
FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
3 Reasons Why AbbVie (ABBV) Is a Great Growth Stock
by Zacks Equity Research
AbbVie (ABBV) possesses solid growth attributes, which could help it handily outperform the market.
AbbVie Settles Humira Litigation With Boehringer Ingelheim
by Zacks Equity Research
AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.
Top Ranked Income Stocks to Buy for May 8th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, May 8th.
The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo
Top Ranked Income Stocks to Buy for May 6th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 6th.
Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Novo Nordisk's (NVO) earnings and sales miss estimates in the first quarter of 2019.
Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod
by Kinjel Shah
Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.
The Zacks Analyst Blog Highlights: Facebook, Comcast, AbbVie, Union Pacific and Air Products
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Comcast, AbbVie, Union Pacific and Air Products
Top Stock Reports for Facebook, Comcast & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Comcast (CMCSA) and AbbVie (ABBV).
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
AbbVie (ABBV) Upgraded to Buy: Here's Why
by Zacks Equity Research
AbbVie (ABBV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
3 Reasons Why Growth Investors Shouldn't Overlook AbbVie (ABBV)
by Zacks Equity Research
AbbVie (ABBV) is well positioned to outperform the market, as it exhibits above-average growth in financials.
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Raises EPS View
by Zacks Equity Research
AbbVie (ABBV) beats first-quarter estimates for both earnings and revenues. Biosimilar competition impacts Humira sales in ex-U.S. markets. Growth in Imbruvica sales offsets Humira decline.
AbbVie (ABBV) Beats Q1 Earnings and Revenues, Shares Up
by Zacks Equity Research
AbbVie's (ABBV) first-quarter 2018 earnings and revenues both beat estimates. The company raised its guidance for adjusted earnings in 2019.
Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates?
by Kinjel Shah
While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.
Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
by Kinjel Shah
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q1.
5 Turnaround Earnings Charts You Must See
by Tracey Ryniec
They were once some of the hottest stocks on the Street. Are they returning to greatness?